You are using an older browser version. Please use a supported version for the best MSN experience.

AbbVie looks beyond Humira with Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan for about $63 billion, grabbing control of the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira. Fred Katayama reports.
image beaconimage beaconimage beacon